Analysts at StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH – Get Free Report) in a research report issued on Monday. The firm set a “sell” rating on the stock.
ProPhase Labs Stock Up 35.1 %
PRPH opened at $0.44 on Monday. The company has a market capitalization of $10.48 million, a PE ratio of -0.35 and a beta of -0.37. The firm has a 50-day simple moving average of $0.55 and a two-hundred day simple moving average of $1.51. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 52 week low of $0.22 and a 52 week high of $7.48.
Institutional Trading of ProPhase Labs
Hedge funds have recently modified their holdings of the company. SVB Wealth LLC bought a new stake in ProPhase Labs in the fourth quarter worth $36,000. Squarepoint Ops LLC bought a new stake in ProPhase Labs during the fourth quarter worth approximately $40,000. Warberg Asset Management LLC purchased a new stake in ProPhase Labs during the 4th quarter valued at $77,000. Perritt Capital Management Inc raised its stake in shares of ProPhase Labs by 129.1% in the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after acquiring an additional 107,068 shares during the period. Finally, Geode Capital Management LLC raised its position in ProPhase Labs by 26.6% in the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after purchasing an additional 42,793 shares during the period. 9.45% of the stock is owned by hedge funds and other institutional investors.
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Further Reading
- Five stocks we like better than ProPhase Labs
- How to Buy Cheap Stocks Step by Step
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Expert Stock Trading Psychology Tips
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
